Merck & Co., Inc. (MRK) Tax Rate: 13.31%
Is Merck & Co., Inc.’s tax rate high or low?
Merck & Co., Inc.'s tax rate of 13.31% is 48% below its 5-year average of 25.48%, near the low end of its 5-year range (10.96%–80.04%).
The tax rate for Merck & Co., Inc. (MRK) is 13.31%. It is below its 12-month average by 2.74% (13.69%).
MRK Tax Rate Chart
MRK Average Tax Rate Chart
MRK Current vs Average Tax Rate Chart
MRK Tax Rate Metrics
TAX RATE
13.31%
TAX RATE AVG TTM
13.69%
TAX RATE AVG 3Y
29.77%
TAX RATE AVG 5Y
25.48%
TAX RATE AVG 10Y
27.21%
TAX RATE AVG 15Y
26.88%
TAX RATE AVG 20Y
25.42%
CURRENT VS TTM AVG
-2.74%
CURRENT VS 3Y AVG
-55.29%
CURRENT VS 5Y AVG
-47.77%
CURRENT VS 10Y AVG
-51.08%
CURRENT VS 15Y AVG
-50.49%
CURRENT VS 20Y AVG
-47.63%
Merck & Co., Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Tax Rate FAQ
- What is the tax rate for Merck & Co., Inc. (MRK)?
- The tax rate for MRK stock is 13.31%.
- Is Merck & Co., Inc.'s tax rate high or low?
- Merck & Co., Inc.'s tax rate of 13.31% is 48% below its 5-year average of 25.48%, near the low end of its 5-year range (10.96%–80.04%).
- What is the TTM average tax rate for Merck & Co., Inc. (MRK)?
- The TTM average tax rate for MRK stock is 13.69%.
- What is the 3Y average tax rate for Merck & Co., Inc. (MRK)?
- The 3Y average tax rate for MRK stock is 29.77%.
- What is the 5Y average tax rate for Merck & Co., Inc. (MRK)?
- The 5Y average tax rate for MRK stock is 25.48%.
- What is the 10Y average tax rate for Merck & Co., Inc. (MRK)?
- The 10Y average tax rate for MRK stock is 27.21%.
- What is the 15Y average tax rate for Merck & Co., Inc. (MRK)?
- The 15Y average tax rate for MRK stock is 26.88%.
- What is the 20Y average tax rate for Merck & Co., Inc. (MRK)?
- The 20Y average tax rate for MRK stock is 25.42%.
Merck & Co., Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 13.31% |
| 2024-12-31 | 14.06% |
| 2023-12-31 | 80.04% |
| 2022-12-31 | 11.66% |
| 2021-12-31 | 10.96% |
| 2020-12-31 | 22.86% |
| 2019-12-31 | 21.82% |
| 2018-12-31 | 28.82% |
| 2017-12-31 | 62.92% |
| 2016-12-31 | 15.41% |
| 2015-12-31 | 17.44% |
| 2014-12-31 | 30.95% |
| 2013-12-31 | 18.54% |
| 2012-12-31 | 27.92% |
| 2011-12-31 | 12.84% |
| 2010-12-31 | 40.59% |
| 2009-12-31 | 14.83% |
| 2008-12-31 | 20.13% |
| 2007-12-31 | 2.83% |
| 2006-12-31 | 28.73% |
| 2005-12-31 | 37.11% |
| 2004-12-31 | 27.15% |
| 2003-12-31 | 27.20% |
| 2002-12-31 | 29.60% |
| 2001-12-31 | 29.10% |
| 2000-12-31 | 30.56% |
| 1999-12-31 | 31.66% |
| 1998-12-31 | 35.47% |
| 1997-12-31 | 28.60% |
| 1996-12-31 | 29.95% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis